PGCert in Tuberculosis – faculty member biographies

Professor Giovanni Battista Migliori
M.D., FERS, FRCP (Lon)
World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Fondazione S. Maugeri IRCCS, Via Roncaccio 16, 21049, Tradate, Italy; Maugeri Institute, IRCCS, Via Roncaccio 16, 21049 Tradate, Italy

Dr Giovanni Battista Migliori has been the director of the World Health Organization (WHO) Collaborating Centre for TB and Lung Diseases, Fondazione S Maugeri, Care and Research Institute, Tradate, Italy since 2000. He has been the Chair of the WHO Working Group on digital health and coordinator of the Roadmap for TB Elimination in Latin America (ALAT/PAHO/ERS) 2015-present. He is a member of the WHO Working Group Latent TB Infection and co-Author of the resulting guidelines since 2015. Since 2014, he has been the Organiser of the global WHO/ERS Consultation on TB Elimination, co-leader of the resulting documents and co-chair of the ATS/ERS guidelines on TB and MDR-TB management. He was the Secretary General, European Respiratory Society (ERS) from 2012-2016 (September) and from September 2016 he became the Director of the ERS TB Collaborating Centre.

Professor Helen McShane
Professor of Vaccinology, University of Oxford, and Oxford Martin School
Senior Fellow, Oxford Martin School

Helen McShane was a Principal Investigator in the Oxford Martin Programme on Vaccines, which was part of the Oxford Martin School from 2010-15. She remains connected with the School through her role as an Oxford Martin Senior Fellow.

Helen McShane has extensive experience in TB immunology and vaccinology. She is Professor of Vaccinology at the University of Oxford; Wellcome Senior Clinical Research Fellow; Honorary Consultant physician in HIV medicine; and an Academic Foundation Programme Lead. She also chairs the Tuberculosis Vaccine Initiative Advisory Committee.

Helen obtained an intercalated BSc in 1988, followed by a degree in medicine in 1991 (both University of London). In 1997 She was awarded an MRC Clinical Training Fellowship to undertake a PhD with Adrian Hill in Oxford, and was later awarded a PhD in 2001 (University of London). In 2001 she was awarded a Wellcome Clinician Scientist Fellowship, allowing her to complete her clinical training and subsequently awarded a CCST in HIV and GU Medicine in 2003. In 2005, she was awarded a Wellcome Senior Clinical Research Fellowship; this Fellowship was renewed in 2010.

Helen has led the TB vaccine research group at the University of Oxford for 14 years and notably headed the development of MVA85A; one of the most clinically advanced new TB vaccine candidates and the first
to enter human efficacy testing. She collaborates with several research groups in Africa in the conduct of clinical trials and current interests are in immunomonitoring in clinical trials, the development of human mycobacterial challenge models and aerosol delivery of vaccines. Helen has published over 100 peer reviewed publications and has an H-index of 39.

Professor Simon Schaaf
Department of Paediatrics and Child Health, Stellenbosch University

Professor Simon Schaaf is one of the pioneers of research into multidrug-resistant tuberculosis (MDR-TB) and his work has helped to broaden the understanding and management of the disease, particularly in children. His research has covered a range of areas including drug resistance surveillance of TB in children, pharmacokinetics of antituberculosis drugs in children, HIV/TB co-infection, childhood TB diagnosis, TB meningitis and new treatment strategies. He obtained his MMed in Paediatrics from Stellenbosch University, where he also completed his PhD, and is Distinguished Professor in the Department of Paediatrics and Child Health at Stellenbosch University and Tygerberg Hospital. He has published/co-published more than 250 peer-reviewed articles in various journals including Lancet Infectious Diseases, Clinical Infectious Diseases and Paediatrics; published more than 25 book chapters and edited two books. He received an Honorary Membership of The International Union Against Tuberculosis and Lung Disease and in 2014 he received the Order of Mapungubwe (silver) from the President of South Africa.

Professor Andrew Nunn
Senior Scientist and Professor of Epidemiology

Andrew Nunn joined the MRC’s Tuberculosis & Chest Diseases Unit as a statistician in 1966. During the next 20 years he was directly involved in the design, conduct and analysis of the programme of trials conducted under the leadership of Professors Wallace Fox and Denny Mitchison in East Africa, Hong Kong and Singapore which led to the worldwide adoption of short course chemotherapy for tuberculosis.

Following the closure of that unit he joined the MRC’s Uganda AIDS Programme which researched the dynamics of the HIV epidemic in a rural African environment. On his return to the UK he became head of the Division Without Portfolio within the newly formed MRC Clinical Trials Unit with responsibility for developing trials in neglected areas.
Currently, he is an investigator and senior statistician on three international Phase III trials of tuberculosis treatment, one of which, **STREAM**, is the first Phase III trial in multidrug-resistant TB.

**Professor Sir Alimuddin Zumla**

Professor Sir Alimuddin Zumla is dually qualified in medicine(MBChB) and science(PhD). He is accredited in internal medicine and infectious diseases and is a Fellow of The: Royal Colleges of Physicians of London & Edinburgh, Royal College of Pathologists, Royal Society of Biology, and African Academy of Sciences. He was born in Fort Jameson, Zambia (British Northern Rhodesia). As a BEIT Scholar he completed an MSc in Tropical Medicine (Distinction & Mugratroyd prize) and PhD (Alan Woodruff Medal) from The London School of Tropical Medicine and Hygiene. He received international acclaim for rapidly identifying and notifying the 1988 Legionnaires' disease outbreak which he traced back to Broadcasting House, Portland Place, London whilst working as an infectious diseases registrar at Rush Green Hospital in Romford. After four years as senior registrar at the Hammersmith Hospital, Royal Postgrad Medical School, London, he spent three years as Associate Professor at the University of Texas Health Science Centre, Houston, USA, and Visiting Professor at UTH in Lusaka, Zambia, before joining UCL in 1994. Since 1994, Professor Sir Alimuddin Zumla has pioneered and championed the discipline of ‘Global Health’ at UCL with significant effect. He has effectively networked numerous institutions across the world achieving significant ‘unity of purpose’ for poverty related diseases. He is a lead global advocate for developing fair and equitable North-South partnerships where close alignment of capacity development with research is central to his ethos. To take this forward he established the **UNZA-UCLMS R&D Programme** in 1994 – a unique, novel model of 'equitable' mutually beneficial partnerships – which has received several international awards, including The European & Developing Countries Clinical Trials Partnership (EDCTP) ‘Most outstanding ‘Africa-Europe’ Team Award and Trophy’ (November 2016).

Recent awards/accolades: Spinoza Award (Univ.Amsterdam-2011); Order of The Grand Commander of Distinguished Services (GCDS)-First Division from President of Zambia (2012); STOP-TB Partnership-WHO Kochon Prize & Medal (2012); Donald Mackay Medal-The Royal.Soc.Trop.Med&Hyg (2014); The Times Higher Education Award (2014); UCLHospitals-NHS-Fdn Trust Excellence Award for World Class Research (2015); UK-NIHR Senior Investigator Award (2017); Karolinska Institutet, Sweden 'Doctorate honoris causa' for "exceptional contributions to science, healthcare & humanity at large" (2016); Knighthood-Knight Bachelor from Her Majesty the Queen (Birthday Honours List June, 2017) for services to public health and infectious diseases.

Publications: a) 540 peer-reviewed PUBMED articles (Google Scholar H-index=101; i10index=701; and 49,500 citations), b) 19 medical textbooks, including the classics: Manson’s Tropical Diseases (co-ed.GC Cook), Tuberculosis; A Comprehensive Clinical Reference (co-ed.S.Schaaf); Granulomatous Disorders (co-ed. D. James ); Perspectives in Medicine-TB (co-eds: S.Kaufmann&E.Rubin), c) Numerous expert reports and journal themes series (http://www.unza-uclms.org/tb-theme-series).
Professor Christian Lienhardt
MD, DTM, MSc, PhD
Director of Research at the French Institute for Research on Sustainable Development (IRD), Montpellier, France

Professor Christian Lienhardt is in charge of a research portfolio on tuberculosis and co-morbidities. He is an Infectious and Tropical Disease specialist and Clinical Epidemiologist, graduated from the Universities of Strasbourg (France), and London (UK). He worked several years as a clinician in France, and undertook medical relief and health development work with various NGOs in several countries in the Middle East and in Africa (1981-89). He started his research work on leprosy at the London School of Hygiene and Tropical Medicine (UK) and then in Bamako (Mali) (1990-94). He then carried out clinical and epidemiological research on tuberculosis in The Gambia with the UK Medical Research Council (MRC) and then in Senegal with the French Institute for Research on Sustainable Development (IRD) (1994-2004). His research work included observational cohort and case-contact studies, international multicenter randomised controlled trials, and programmatic and operational research studies. He headed the Clinical Trial Division at the International Union Against Tuberculosis and Lung Diseases (The Union) in Paris from 2004 to 2008. He joined the World Health Organization, Geneva (Switzerland) from 2009 until 2018, first as Senior Research Advisor at the Stop TB Partnership, in charge of the TB Research Movement, and then as Team Leader, Research for TB Elimination, at the Global TB Programme, in charge of support and promotion of TB research in high- and medium-TB burden countries, as well as of the evaluation and introduction of new TB drugs and regimens.

Dr Masoud Dara
Senior Advisor of the World Health Organization Office at the European Union

Dr Masoud Dara is a physician and public health expert from Belgium. In addition to his medical degree, he has accomplished several courses and postgraduate studies including courses at London School of Hygiene and Tropical Medicine and Harvard School of Public Health. Dr Dara’s professional career began as a clinician responsible for diagnosis and treating tuberculosis patients and implementing DOTS in rural and urban areas of Iran. Since 1998, Dr Dara has been working with multiple national and international organisations implementing TB control programmes, public health interventions and emergency response. He has worked as the Médecins Sans Frontières programme manager and medical coordinator of several TB control projects in Central Asia from 1998 to 2001. From 2001-03, Dr Dara worked as a WHO Medical Officer in the Russian Federation providing technical assistance to national health authorities and TB control services across the country. From 2003-10, Dr Dara worked as a senior consultant of KNCV Tuberculosis Foundation in different countries mainly in the fields of MDR-TB, TB/HIV and TB-IC.

Since 2008, Dr Dara has been the Chair of scientific working group of TB control in prisons International Union Against Tuberculosis and Lung Diseases. From 2004 to 2010, he has provided technical assistance to different countries as a GLC consultant and MDR-TB and TB-IC trainer. Since 2010, Dr Dara has joined the WHO providing technical assistance to the Member States in prevention and control of drug resistant TB. Since 2012, he is based at the WHO Office at the European Union in Brussels and currently functions as
a Senior Advisor for communicable diseases and emergency response including Ebola. Dr Dara speaks English, French, Russian, Persian and Dutch.

**Dr Daniela Cirillo**  
MD, PhD  
San Raffaele Hospital, Milan, Italy

Dr Daniela Cirillo is Head of the Emerging Bacterial Pathogens Unit at the San Raffaele Scientific Institute in Milan, Italy. She is a member of the Scientific and Technical Advisory Group of the Stop-TB Department (WHO) and Co-Chair of the New Diagnostic Working Group of the Stop-TB partnership. Her main interests are: new diagnostic for MDR/XDR-TB, M.tuberculosis pathogenesis, virulence markers and providing technical assistance for implementation of new tools for tuberculosis diagnosis, Quality Assurance Programmes.

**Professor Onn Min Kon**

Professor Onn Min Kon is a respiratory physician and head of the tuberculosis service at Imperial College Healthcare NHS Trust. He is professor of respiratory medicine at the National Heart & Lung Institute, Imperial College London. He is chair of the UK National Multidrug-resistant Tuberculosis (MDR-TB) clinical advice service. He is a member of the National Tuberculosis Oversight Group and chairs the Joint Tuberculosis Committee. In addition to a general respiratory clinic, he runs a sarcoidosis and interstitial lung disease clinic. He is the senior bronchoscopist for the respiratory service which offers a tertiary endobronchial ultrasound service. Professor Kon also organises the London advanced tuberculosis course. Expertise in Chest medicine, tuberculosis, sarcoidosis, interventional bronchoscopy, airway infections, interstitial lung disease and airway diseases.
Dr Marc Lipman
Reader of Respiratory Medicine.

My research aim is to provide the evidence base to enable people at risk of mycobacterial disease, including TB and related conditions such as HIV infection, to access and obtain the highest quality care. My work concerns the interaction between the human host, the microbe and the environment in which they find themselves. It focuses on three main areas: 1. operational and economic health services research (including management of the hard to reach and hard to treat, service evaluation, and modelling of infection), 2. diagnostics (both microbiology and immune-based), 3. treatment and treatment responses in HIV negative and co-infected individuals (including therapy-related paradoxical reactions).

Marc is an Associate Professor and Consultant in Respiratory & HIV Medicine at University College London, and Royal Free London NHS Foundation Trust. He is Director of UCL-TB, UCL’s cross-disciplinary TB research grouping; and Lead for TB Services at the Royal Free. His research focuses on mycobacterial disease, respiratory infection and HIV - with a particular interest in translational and health services research. He has served on national and international committees, including UK NICE TB Guideline Group and British HIV Association HIV/TB co-infection Working Party. He is Chair of the British Thoracic Society, TB Specialist Advisory Group. He has published over 280 peer-reviewed manuscripts.

Dr Bernd Eisele
M.D.

Dr Bernd Eisele has been CEO of VPM since 2008 and Chief Medical Officer since 2003. From 1997-2002 he was Medical Director and Head of Medical Marketing of Region 6 in Solvay Pharmaceuticals GmbH, Hannover. Region 6 comprised Canada, Asia, the Middle East, India, Australia, and South Africa. Bernd was responsible for the planning and conduct of local and region-wide marketing campaigns for Solvay's influenza vaccine and for its cardiovascular, gastroenterology, gynecology, and psychiatry products. Additionally, Bernd planned and supervised the company's pivotal trials within the Region which were needed for local registrations (eg for PR China). In 2002, he was appointed Global Product Director for psychiatry and became responsible for the worldwide marketing of Solvay Pharmaceuticals’ psychiatry products. Bernd had joined Solvay in 1996 and was responsible for the international phase III development programme of one of Solvay’s leading cardiovascular products. Bernd Eisele began his career in the industry as a Clinical Project Manager at Behringwerke AG in 1988. In various positions Bernd was responsible for the clinical development of recombinant and transgenic products in clinical phases I – III. Bernd Eisele holds a doctorate in medicine from Heidelberg Medical University (1986).
Dr Delia Goletti
MD, PhD,
Infectious Diseases specialist

In 1992, Dr Delia Goletti joined the Laboratory of Immunoregulation at the National Institutes of Health (chief Dr Fauci) working on HIV pathogenesis. In 1999 she joined the National Institute for Infectious Diseases in Rome. She has clinical duties on the tuberculosis (TB) clinic and responsibility of the Translational Research Unit where she works on TB pathogenesis, TB immunodiagnostic tests and impact of Hemiths infection on HIV and TB disease.

Dr Dominik Zenner

Dr Dominik Zenner is Senior Migration Health Advisor for the Regional Office for the EEA, the EU and NATO of the International Organization for Migration. Previously he worked as Consultant Epidemiologist and head of TB screening in the national TB section in Public Health England, UK.

He helped develop and implement the TB strategy for England including leading the roll out of the national LTBI screening programme and led on health aspects of the UK refugee programme and the UK pre-entry TB screening programme. He has a keen and demonstrated academic and strategic interest in infectious disease epidemiology and migration health, including several high impact publications and has won several prizes for TB-related studies, including the Young Investigator award from the European Respiratory Society. His work has informed national and international policy, including WHO guidelines.
Dr Alistair Story
Founder and Clinical Lead of the pan-London Find&Treat Service based out of University College London Hospitals.

His core expertise is in tackling tuberculosis and other communicable diseases among homeless people, drug and alcohol users, prisoners and destitute migrants. His research interests include outreach, integrating point of care diagnostics on the street, case management, the inclusion of service users within MDTs and the use of mobile internet technologies to promote engagement with health services and treatment continuity. He is an original member of the Faculty for Homeless and Inclusion Health and the Pathway Team and senior lecturer at the Farr Institute University College London.

Professor Adrian Martineau
B Med Sci DTM&H MRCP PhD FRSB
Clinical Professor of Respiratory Infection and Immunity

Adrian gained a BMedSci degree in Epidemiology and Public Health from Newcastle University in 1995, and graduated from Newcastle Medical School the following year. He then gained a Diploma in Tropical Medicine and Hygiene from Liverpool University before working as a Medical Officer in South Africa. He returned to Liverpool to continue medical training in 1999, and became a member of the Royal College of Physicians in 2001. Adrian joined Queen Mary as a lecturer in Respiratory Medicine in 2002, and established a programme of laboratory and clinical research into the immunomodulatory actions of vitamin D in tuberculosis. He received his PhD in 2010, and is currently conducting clinical trials of vitamin D supplementation to prevent respiratory infections and non-communicable diseases in the UK, South Africa and Mongolia. He was elected a Fellow of the Royal Society of Biology in 2017.

Adrian's primary research interest is in the effects of vitamin D on human health. His work combines laboratory investigation of the effects of vitamin D on the immune system with a series of multi-centre clinical trials and meta-analyses, investigating the potential role of vitamin D supplementation as an agent to prevent respiratory infections and non-communicable diseases. He is Clinical Chief Investigator for the Vitamin D and Longevity trial VIDAL (an NIHR-funded study investigating effects of vitamin D supplementation on all-cause mortality in UK adults aged 65-84 years) and the ViDiKids trial (a MRC-funded study investigating whether vitamin D can prevent tuberculosis infection among primary schoolchildren in Cape Town, South Africa). He sits on the NICE Public Health Advisory Committee on Vitamin D, and works clinically in the Tuberculosis Clinic at Barts Health NHS Trust. Adrian has an active PhD programme and enquiries from prospective PhD or MD students interested in respiratory infection and/or vitamin D are welcome.
Dr Martin Dedicoat
Consultant in Infectious Diseases at Birmingham Heartlands Hospital

Dr Martin Dedicoat is an Infectious Diseases Consultant in Birmingham. He trained in London, Ecuador, Birmingham and South Africa. His main clinical interests are in tuberculosis and non-tuberculous mycobacteria.

Dr Onno Akkerman
Respiratory Physician Specialist, Head of the MDR-TB Unit, UMCG - Universitair Medisch Centrum Groningen, The Netherlands

Since 2011, Onno has worked as a chest physician at the department of Pulmonary Diseases and Tuberculosis of the UMCG where he is responsible for the medical care of the Tuberculosis Center Beatrixoord (Haren, the Netherlands).

Dr Timothy Walker
Academic Clinical Lecturer and Doctor in Microbiology/Infectious Diseases

Timothy studies how DNA analysis can be used to predict drug resistance, understand transmission of infections, and inform patient care.
Dr Veronica White

Dr Veronica White is Respiratory Consultant and Clinical Director for Respiratory Medicine and Clinical Lead for the TB service at Barts Health NHS Trust, which has one of the largest TB services in Western Europe.

Dr James Seddon

James Seddon is a Clinical Lecturer in Paediatric Infectious Diseases at Imperial College London. He divides his time between clinical work and research. His major area of research is that of children with tuberculosis, specifically drug-resistant forms.

He studied medicine at Corpus Christi College, Cambridge and Imperial College London and has carried out paediatric training in both UK and Australia. He has worked as a doctor for Médecins Sans Frontières in Côte d'Ivoire and most recently has completed a PhD in Cape Town on paediatric multidrug-resistant tuberculosis.

Professor Raquel Duarte

M.D., MSc, PhD.

Secretary of State of Health, Portugal. Respiratory Consultant and National TB lead. European Respiratory Society Chair for Group 10.2. Coordinator of the National Reference Center for M/XDR Tuberculosis. Member of the Assembly 10 Long Range Planning Committee of European Respiratory Society. Secretary General of The Union Europe Region. Member of the task force from European Respiratory Society to work with the Thorax Latino-American Society on the road-map on tuberculosis elimination in Latin America. Member of the ECDC Ad hoc scientific panel.
Professor Stephen Gillespie has worked in Kenya researching the relationship between malaria and lower respiratory tract infection and the prevalence of parasitic infection in children in Kilifi, Kenya. He has investigated a cholera epidemic and vaccine failures in Guerrero, Mexico. He has been working in collaboration with colleagues at Kilimanjaro Christian Medical Centre since 1988 where he has, variously, studied respiratory and parasite diagnostics and novel antimalarials, anti-helminthics and anti-tuberculosis agents. His main research activity is in the area of tuberculosis drug development.

For the last 25 years Stephen Gillespie has been involved in various aspects of tuberculosis diagnosis and drug development. This has included the evaluation of new candidate anti-tuberculosis agents in vitro. This work has expanded into studies of the molecular mechanisms of resistance and the development of model systems to measure the fitness deficits found in resistant strains. He has been involved in the development of fluoroquinolones for tuberculosis having performed early bacterial activity studies and clinical trials of ciprofloxacin. More recently he has led the group working on the clinical development of moxifloxacin in collaboration with the Global Alliance for TB Drug Development as Chief Investigator of the REMox TB study. He later went on to be the coordinating investigator for the TB Alliance STAND trial (Shortening Treatment by Advancing New Drugs). He is also one of the Chief Investigators of the PanACEA consortium that links European and African research groups in enhancing anti-tuberculosis therapy.

He has an extensive record of developing novel microbiological diagnostics. Most recently, he has developed SLIC (Scattered Light Integrating Collector), which performs phenotypic antibiotic susceptibility testing in less than 30 minutes. This innovation recently won a Longitude Prize Discovery Award. In addition he has developed the Molecular Bacterial Load Assay, an innovative way of detecting, quantifying and determining the viability of bacteria in a single test that allows both diagnosis and the monitoring of treatment response.
Dr Heinke Kunst
MD, MRCP, MSc.
Senior Lecturer in Respiratory Medicine

Heinke Kunst trained as a specialist registrar in Respiratory Medicine in the North Thames London rotation. She subsequently did an MSc and Diploma in Tropical Medicine at the LSHTM. In 2005 she was appointed as Consultant in Respiratory Medicine at Heart of England NHS Foundation Trust. She was tuberculosis lead and Honorary Senior Lecturer at the University of Birmingham. Heinke joined Queen Mary in 2015 to develop a clinical research group in tuberculosis. Heinke Kunst is a Senior Lecturer at Barts and The London School of Medicine and Dentistry, Queen Mary University of London and Honorary Consultant in Respiratory Medicine at Barts Health NHS trust. She is the Research and development lead for Respiratory Medicine of the CAG (Clinical Academic Group) at Barts Health. Her main research interest is in migrant Health and Translational Research Themes in tuberculosis and latent tuberculosis infection.

Dr Simon Tiberi

Dr Simon Tiberi is a Consultant Physician and Honorary Senior Lecturer in Infectious Diseases at Barts Health NHS Trust and Queen Mary University of London. He works in three hospitals in east London working in OPAT, ID and TB clinics, providing inpatient care and consultations. Dr Tiberi is a Clinical Advisor to the British Thoracic Society Multidrug resistant Tuberculosis Clinical advisory service. He is also TB secretary for the European Respiratory Society and Vice Chair of the Global TB Network Consilium. His research interests focus on mycobacteria, treatment of drug resistant and respiratory infections. He is currently involved in a number of clinical trials, translational and health service research programmes. Dr Tiberi has published in over 50 papers and several book chapters in the last three years. He is course director of the Queen Mary University of London TB postgraduate certificate programme.